mRNA Technology Newsletter
Issue #2September 15, 20257 studies

A cholesterol tweak quietly changed where mRNA goes

The mRNA revolution is hitting its stride. From vaccines that precisely target specific cells to cancer treatments that hijack the body's own immune system, researchers are pushing these molecular messengers far beyond their COVID-19 origins.

๐ŸŽฏ Smart cholesterol turns mRNA into a precision missile

Researchers cracked a major mRNA delivery problem by turning cholesterolโ€”which makes up about half of all lipid nanoparticle moleculesโ€”into a targeting system.

  • Adding mannose sugar to cholesterol in lipid nanoparticles redirected mRNA away from liver cells (hepatocytes) and toward immune cells called Kupffer cells and liver sinusoidal endothelial cells

  • The targeting worked because these immune cells express high levels of mannose receptors (CD206), while liver cells don't

  • Shorter PEG chains on the nanoparticles improved targeting by allowing faster shedding in circulation, exposing more mannose for binding

Why it matters: Most mRNA therapies get trapped in liver cells due to natural protein coating, limiting their use for diseases affecting other cell types. This cholesterol modification approach could unlock mRNA treatments for immune disorders, blood vessel diseases, and other conditions requiring precise cellular targeting.

Top 20% journal ๐Ÿ”— Bioconjugate chemistry ๐Ÿ—“๏ธ Sep 11

Key Findings

๐Ÿ”ฌ Omicron boosters work better with Pfizer than Moderna

  • In a 706-person clinical trial, Omicron BA.1 boosters reduced COVID-19 incidence 2.56-fold compared to original vaccine boostersโ€”but only for Pfizer recipients

  • Moderna recipients showed no difference between Omicron and original boosters (risk ratio 1.04)

  • The trial tracked participants for months after vaccination, measuring both antibody levels and actual COVID-19 infections

๐Ÿ’ก Vaccine effectiveness may depend on specific manufacturer formulations, not just the targeted viral strain.
Top 20% journal ๐Ÿ”— Vaccine ๐Ÿ—“๏ธ Sep 10

๐Ÿ’‰ Tumor-activated cancer treatment stays dormant until needed

  • Scientists engineered mRNA encoding a "locked" IL-12 protein that only activates when it encounters tumor-specific enzymes (MMP-2)

  • The system allows safe systemic delivery of a powerful immune-stimulating protein that would normally cause dangerous side effects

  • In mice, the approach eliminated tumors while avoiding the immune toxicity that has limited IL-12 cancer treatments

๐Ÿ’ก Conditional activation could make potent cancer immunotherapies safer by limiting their effects to tumor sites.
๐Ÿฅ‰ Top 5% journal ๐Ÿ”— Nano letters ๐Ÿ—“๏ธ Sep 10

๐Ÿซ Inhaled nanoparticles reach the liver, not just lungs

  • Neutral-charged mRNA nanoparticles delivered via nebulizer targeted the liver, while charged particles stayed in the lungs

  • In diabetes mice, inhaled delivery of insulin-like hormone mRNA (dulaglutide) controlled blood sugar effectively

  • In liver disease mice, inhaled enzyme mRNA helped maintain body weight and preserve liver function

๐Ÿ’ก Inhalation could offer a gentler, non-invasive route for liver-targeted gene therapies.
๐Ÿฅ‰ Top 5% journal ๐Ÿ”— Nano letters ๐Ÿ—“๏ธ Sep 8

๐Ÿฉธ mRNA prevents blood clots by targeting vessel walls

  • Researchers developed lipid nanoparticles that specifically target blood vessel cells to deliver clot-dissolving protein mRNA

  • The system prevented deep vein thrombosis in mice by producing tissue plasminogen activator (TPA) directly at vessel walls

  • This approach avoids bleeding complications of systemic blood thinners by localizing the anti-clotting effect

๐Ÿ’ก Targeted mRNA delivery could provide safer alternatives to current blood clot treatments.

๐Ÿฆ  Norovirus vaccine protects across multiple viral strains

  • A five-strain mRNA vaccine induced antibodies against all included norovirus types in both mice and non-human primates

  • The vaccine produced immune responses comparable to traditional virus-like particle vaccines but with similar durability

  • Noroviruses cause 18% of diarrheal disease globally with no current vaccines available

๐Ÿ’ก Multivalent mRNA vaccines could provide broad protection against highly variable viruses like norovirus.

๐Ÿง  Neutrophil-hijacking nanoparticles treat stroke

  • Lipid nanoparticles loaded with anti-inflammatory drug exploited neutrophil migration to cross the blood-brain barrier and reach stroke sites

  • In mice with induced strokes, the targeted treatment reduced brain damage by 45% and cut inflammatory markers by over 50%

  • The approach uses neutrophils' natural tendency to rush toward damaged tissue as a delivery vehicle

๐Ÿ’ก Hijacking immune cell trafficking patterns could enable drug delivery to previously unreachable tissues.
๐Ÿฅ‰ Top 5% journal ๐Ÿ”— Acta biomaterialia ๐Ÿ—“๏ธ Sep 14

Implications

These studies reveal mRNA technology's rapid evolution from simple vaccines to sophisticated therapeutic platforms. By solving targeting challenges and developing conditional activation systems, researchers are positioning mRNA treatments to address cancer, blood disorders, and neurological diseases with unprecedented precision.

Studies in this issue

Primary sources used for this newsletter.

  1. Using synthetic lipid nanoparticles to deliver mRNA to blood vessel lining cells to prevent vein blood clots
    key findingJournal of controlled release : official journal of the Controlled Release Society2025-09-13PMID 40946051
  2. Immune responses from mRNA vaccines producing norovirus proteins in mice and primates
    key findingMolecular therapy : the journal of the American Society of Gene Therapy2025-09-14PMID 40946165